# psoriasis - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 49386
- Completion tokens: 21814
- Reasoning tokens: 0
- Total tokens: 71200
- API requests reported: 4
- Elapsed seconds: 119.032
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: DeepSeek

---
# Multidimensional Interpretation of Psoriatic Lesional Skin Transcriptomic Data

## 1. Overall Biological Interpretation

The transcriptomic comparison of psoriatic lesional skin versus normal control skin reveals a highly coordinated inflammatory and epidermal-remodeling program. Of the 100 selected genes, 90 are upregulated and 10 are downregulated, with all 100 genes passing FDR ≤ 0.01. The dominant signal is a massive upregulation of **IL-36 family cytokines (IL36A, IL36G, IL36RN)** and **IL-20 family cytokines (IL19, IL20, IL26)**, together with **antimicrobial peptides (DEFB4A, DEFB4B, DEFB103A, DEFB103B, S100A7, S100A7A, S100A8, S100A12, PI3)**. This is accompanied by a striking activation of **epidermal differentiation/cornified envelope genes (SPRR2A–G, SPRR3, LCE3A, LCE3D, KRT6A)** and **protease/antiprotease systems (SERPINB3, SERPINB4, KLK13, TMPRSS11D, PRSS27)**. The pattern is consistent with the well-established psoriasis paradigm of IL-17/IL-36-driven inflammation with aberrant keratinocyte differentiation and barrier dysfunction. The downregulated genes (BTC, CYP2W1, SAPCD1, UGT3A2, WAKMAR1, and several uncharacterized loci) are fewer and more heterogeneous, providing less coherent program-level signal.

## 2. Core Biological Programs

### Program 1: IL-36/IL-20 Cytokine-Driven Inflammation
- **Direction**: Upregulated
- **Supporting genes**: IL36A (log2FC=11.37), IL36G (log2FC=5.68), IL36RN (log2FC=3.01), IL19 (log2FC=7.58), IL20 (log2FC=5.67), IL26 (log2FC=4.36), IRAK2 (log2FC=2.08), ZC3H12A (log2FC=3.85)
- **Standardized pathway**: Reactome "Interleukin-36 pathway" (R-HSA-9014826); Reactome "Interleukin-20 family signaling" (R-HSA-8854691); KEGG "Cytokine-cytokine receptor interaction"
- **Biological rationale**: IL36A and IL36G are among the most strongly upregulated genes in the dataset, and their receptor antagonist IL36RN is also induced—consistent with a counter-regulatory attempt. The IL-20 family members (IL19, IL20, IL26) signal through shared receptor complexes and are established drivers of keratinocyte hyperproliferation in psoriasis. IRAK2 is a downstream signaling component of TLR/IL-1R family pathways, and ZC3H12A (Regnase-1) is an inflammation-induced RNA-binding protein that regulates cytokine mRNA stability. Together these genes define a coherent IL-36/IL-20-driven inflammatory axis.
- **Evidence strength**: Strong direct statistical support (all genes FDR < 1e-60); pathway annotations from Reactome and KEGG; extensive published literature on IL-36 and IL-20 in psoriasis. Limitation: the dataset does not include IL17A/F themselves, so the IL-17 connection is inferred through downstream targets and pathway co-membership rather than direct measurement.

### Program 2: Antimicrobial Peptide and S100 Alarmin Response
- **Direction**: Upregulated
- **Supporting genes**: DEFB4A (log2FC=11.18), DEFB4B (log2FC=11.03), DEFB103A (log2FC=5.76), DEFB103B (log2FC=5.75), S100A7 (log2FC=7.09), S100A7A (log2FC=9.83), S100A8 (log2FC=7.73), S100A12 (log2FC=8.33), PI3 (log2FC=9.24)
- **Standardized pathway**: GO "Antimicrobial humoral response" (GO:0019730); GO "Response to lipopolysaccharide" (GO:0032496); KEGG "Staphylococcus aureus infection"
- **Biological rationale**: The massive induction of β-defensins and S100 family proteins is a hallmark of psoriatic epidermis. These molecules serve dual roles as antimicrobial effectors and as alarmins that amplify inflammation through pattern recognition receptors (e.g., S100A8/S100A12 activating TLR4). The coordinated upregulation of multiple independent AMP families indicates an innate immune barrier response that is both a defense mechanism and a pro-inflammatory amplifier.
- **Evidence strength**: Strong direct statistical support; pathway/GO annotations retrieved; extensive literature support for S100/defensin upregulation in psoriasis. Limitation: whether these changes are causal drivers or downstream consequences of IL-17/IL-36 signaling cannot be determined from expression data alone.

### Program 3: Aberrant Epidermal Differentiation and Cornified Envelope Formation
- **Direction**: Upregulated
- **Supporting genes**: SPRR2A (log2FC=7.31), SPRR2B (log2FC=6.38), SPRR2D (log2FC=5.92), SPRR2E (log2FC=3.99), SPRR2F (log2FC=7.22), SPRR2G (log2FC=4.75), SPRR3 (log2FC=7.18), LCE3A (log2FC=8.30), LCE3D (log2FC=5.31), KRT6A (log2FC=4.30), GJB2 (log2FC=4.42), GJB6 (log2FC=3.02)
- **Standardized pathway**: Reactome "Formation of the cornified envelope" (R-HSA-6809371); GO "Epidermis development" (GO:0008544)
- **Biological rationale**: The coordinated upregulation of small proline-rich proteins (SPRRs), late cornified envelope proteins (LCE3A, LCE3D), and KRT6A reflects the hyperproliferative and aberrantly differentiated keratinocyte phenotype of psoriatic plaques. LCE3 genes are particularly notable because deletion of LCE3B/LCE3C is a replicated psoriasis risk locus; the induction of LCE3A/LCE3D here suggests compensatory or disease-associated epidermal remodeling. The gap junction proteins GJB2 and GJB6 (connexins) are consistent with altered keratinocyte communication during hyperproliferation.
- **Evidence strength**: Strong direct statistical support; Reactome pathway annotation; STRING network evidence shows co-membership among SPRR/LCE genes. Limitation: many of these genes are also induced in other hyperproliferative skin conditions (wound healing, other inflammatory dermatoses), so specificity to psoriasis is not established by this dataset alone.

### Program 4: Protease/Antiprotease Imbalance and Barrier Remodeling
- **Direction**: Upregulated
- **Supporting genes**: SERPINB3 (log2FC=6.74), SERPINB4 (log2FC=9.12), SERPINB11 (log2FC=4.47), SERPINB13 (log2FC=3.09), KLK13 (log2FC=4.05), TMPRSS11D (log2FC=7.75), PRSS27 (log2FC=4.25), HPSE (log2FC=2.92)
- **Standardized pathway**: GO "Epidermis development" (GO:0008544); protease inhibitor activity (GO molecular function)
- **Biological rationale**: The coordinated induction of serine protease inhibitors (SERPINB family) alongside kallikrein-related peptidase KLK13 and other proteases (TMPRSS11D, PRSS27) suggests a perturbed protease-antiprotease balance in the psoriatic epidermis. SERPINB3/B4 are classical markers of psoriatic keratinocyte activation and are induced by IL-17/IL-22. HPSE (heparanase) degrades extracellular matrix heparan sulfate and can release growth factors, potentially contributing to the altered epidermal microenvironment.
- **Evidence strength**: Moderate-to-strong direct statistical support; STRING network shows SERPINB3/B4/B13 clustering with CTSG. Limitation: the functional consequence of the protease-antiprotease imbalance (net proteolysis vs. net inhibition) cannot be inferred from expression alone; activity assays would be required.

### Program 5: Neutrophil Chemotaxis and Innate Immune Cell Recruitment
- **Direction**: Upregulated
- **Supporting genes**: CXCR2 (log2FC=2.70), CXCL13 (log2FC=5.89), S100A8 (log2FC=7.73), S100A12 (log2FC=8.33), PLA2G4D (log2FC=4.61), PLA2G4E (log2FC=2.47), GPR15LG (log2FC=5.52)
- **Standardized pathway**: KEGG "Cytokine-cytokine receptor interaction"; GO "Response to lipopolysaccharide" (GO:0032496)
- **Biological rationale**: CXCR2 is the receptor for neutrophil chemoattractants (CXCL1/2/8), and its upregulation in lesional skin is consistent with the neutrophilic microabscesses (Munro microabscesses) characteristic of psoriasis. S100A8/A12 are both alarmins and neutrophil chemoattractants. CXCL13 is a B-cell/T-follicular-helper chemoattractant, suggesting lymphoid infiltration in addition to the myeloid/neutrophil component. The cytosolic phospholipase A2 family members PLA2G4D/E generate eicosanoid mediators that can amplify inflammation. GPR15LG (GPR15 ligand) is involved in lymphocyte homing to skin.
- **Evidence strength**: Moderate direct statistical support; pathway co-membership in cytokine-cytokine receptor interaction. Limitation: CXCL13 elevation could reflect tertiary lymphoid structures that are present in a subset of psoriatic lesions rather than a universal feature; the dataset cannot distinguish which cell type expresses these genes (bulk tissue).

## 3. Key Genes and Interaction Modules

### Module 1: IL-36 Signaling Axis (IL36A, IL36G, IL36RN, IL1RAP)
- **Direction**: All upregulated (IL36A log2FC=11.37, IL36G log2FC=5.68, IL36RN log2FC=3.01)
- **Role**: The IL-36 axis is a central driver of psoriatic inflammation. IL36A and IL36G are agonists that signal through IL1RL2/IL1RAP; IL36RN is the natural antagonist. The co-induction of agonist and antagonist suggests an active, partially counter-regulated inflammatory loop.
- **Interaction nature**: STRING records show direct physical interaction between IL36RN and IL1RL2 (confidence=0.999), IL36RN and IL36B (confidence=0.989), and IL36RN with IL1RAP (confidence=0.854). These are protein-protein interaction records from curated databases, not inferred from this dataset.

### Module 2: Antimicrobial Peptide Cluster (DEFB4A, DEFB4B, DEFB103A, DEFB103B)
- **Direction**: All strongly upregulated (log2FC 5.75–11.18)
- **Role**: β-defensins are dual-function antimicrobial peptides and chemoattractants. The near-identical log2FC values for DEFB4A/DEFB4B and DEFB103A/DEFB103B reflect their high sequence homology and likely co-regulation.
- **Interaction nature**: STRING network shows CCR6 as a connecting node (DEFB103A, DEFB4A, DEFB4B co-membership). These genes are genomic neighbors in the β-defensin cluster on chromosome 8p23.1, so their co-regulation likely reflects shared regulatory elements. This is pathway co-membership/co-regulation, not necessarily direct physical interaction.

### Module 3: S100 Alarmin Network (S100A7, S100A7A, S100A8, S100A12, FABP5)
- **Direction**: All strongly upregulated (log2FC 3.65–9.83)
- **Role**: S100A7/A7A (psoriasin) and S100A8/A12 are alarmins that activate innate immune receptors and amplify inflammation. FABP5 (log2FC=3.64) is a lipid-binding protein co-expressed with S100A7 in psoriatic epidermis.
- **Interaction nature**: STRING shows S100A7 as a network hub connecting FABP5, S100A12, S100A7A, SERPINB3, SERPINB4. This likely reflects co-expression in the same keratinocyte differentiation program rather than direct physical binding. Direct physical interaction between S100A8/A9 (calprotectin) is established in the literature, but S100A7-S100A12 physical interaction is not established by the records retrieved.

### Module 4: Cornified Envelope Genes (SPRR2A–G, SPRR3, LCE3A, LCE3D, KRT6A)
- **Direction**: All upregulated (log2FC 3.99–8.30)
- **Role**: These genes define the terminal differentiation program of keratinocytes. Their coordinated induction reflects the altered differentiation trajectory in psoriasis (hyperproliferation with premature/aberrant cornification).
- **Interaction nature**: STRING network shows extensive co-membership among SPRR genes and LCE genes. These are pathway co-members in Reactome "Formation of the cornified envelope" (R-HSA-6809371). They do not physically interact as proteins; rather, they are sequentially expressed components of the same structural program.

### Module 5: SERPINB Protease Inhibitor Cluster (SERPINB3, SERPINB4, SERPINB11, SERPINB13)
- **Direction**: All upregulated (log2FC 3.09–9.12)
- **Role**: SERPINB3/B4 are classical markers of psoriatic keratinocyte activation. They inhibit cysteine and serine proteases and may protect keratinocytes from immune-cell-derived proteases. STRING network shows co-membership with CTSG (cathepsin G), suggesting a functional relationship with neutrophil proteases.
- **Interaction nature**: STRING shows CTSG as a connecting node (SERPINB13, SERPINB3, SERPINB4). SERPINs inhibit proteases through direct physical binding, and CTSG is a known target of SERPINB family members—this is plausibly a direct physical interaction, though the specific SERPINB-CTS G pairs should be confirmed experimentally.

### Module 6: CXCR2 and Neutrophil Recruitment
- **Direction**: Upregulated (CXCR2 log2FC=2.70)
- **Role**: CXCR2 mediates neutrophil chemotaxis to the skin. Its upregulation is consistent with the neutrophilic infiltrate characteristic of psoriatic plaques.
- **Interaction nature**: CXCR2 is a receptor; its ligands (CXCL1/2/8) are not in the selected gene list. The relationship between CXCR2 upregulation and S100A8/A12 (both neutrophil chemoattractants) is functional/pathway co-membership, not direct physical interaction.

### Module 7: CD274 (PD-L1) Upregulation
- **Direction**: Upregulated (log2FC=3.44)
- **Role**: CD274 encodes PD-L1, an immune checkpoint ligand. Its upregulation in lesional skin may represent a counter-regulatory mechanism attempting to limit T-cell-mediated inflammation, or may reflect the presence of PD-L1-expressing cells (e.g., dendritic cells, macrophages) in the infiltrate.
- **Interaction nature**: CD274 interacts with PDCD1 (PD-1) on T cells; this is a direct physical receptor-ligand interaction, but PDCD1 is not in the selected gene list. The functional significance in psoriasis (a Th17-mediated disease) is debated—checkpoint blockade can trigger or exacerbate psoriasis in some patients, suggesting the PD-L1/PD-1 axis may restrain disease.

### Module 8: WNT5A and Non-Canonical Wnt Signaling
- **Direction**: Upregulated (log2FC=2.53)
- **Role**: WNT5A is a non-canonical Wnt ligand implicated in skin inflammation and fibrosis. Its upregulation may contribute to the altered keratinocyte proliferation and dermal changes in psoriasis.
- **Interaction nature**: WNT5A signaling through ROR2/FZD receptors is a regulatory interaction; the specific receptors are not in the selected gene list. This is a pathway co-membership/regulatory relationship, not a direct physical interaction demonstrated in this dataset.

### Module 9: Downregulated Genes (BTC, CYP2W1, SAPCD1, UGT3A2, WAKMAR1)
- **Direction**: Downregulated (log2FC from −2.84 to −6.25)
- **Role**: BTC (betacellulin) is an EGFR ligand; its downregulation is interesting given that EGFR signaling is typically upregulated in hyperproliferative skin. CYP2W1 is a xenobiotic-metabolizing enzyme. SAPCD1 and UGT3A2 have limited functional annotation. WAKMAR1 is a long non-coding RNA. The biological coherence of this downregulated set is limited, and the functional significance is unclear.
- **Interaction nature**: No clear interaction module; these are heterogeneous genes with limited shared biology.

### Module 10: PLA2G4D/PLA2G4E and Eicosanoid Signaling
- **Direction**: Upregulated (PLA2G4D log2FC=4.61, PLA2G4E log2FC=2.47)
- **Role**: These cytosolic phospholipase A2 family members release arachidonic acid from membrane phospholipids, providing substrate for prostaglandin and leukotriene synthesis. STRING network shows GNAS as a connecting node (HRH2, PLA2G4D, PLA2G4E), suggesting G-protein-coupled receptor-mediated regulation.
- **Interaction nature**: GNAS (Gαs) can regulate PLA2 activity through GPCR signaling; this is a regulatory interaction, not direct physical binding.

## 4. Validation Priorities

### Priority 1: IL-36 Signaling Axis as a Therapeutic Target
- **Classification**: Therapeutic target
- **Rationale**: IL36A and IL36G are among the most strongly upregulated genes (log2FC 11.37 and 5.68), and the IL-36 pathway is a recognized driver of psoriatic inflammation. The co-upregulation of IL36RN (the natural antagonist) suggests an endogenous counter-regulatory attempt that is insufficient.
- **Current evidence**: Direct statistical support (FDR < 1e-90); Reactome pathway annotation (Interleukin-36 pathway); STRING direct interaction records (IL36RN-IL1RL2, IL36RN-IL1RAP); published literature on IL-36 in psoriasis.
- **External evidence**: IL-36 receptor antagonists (e.g., spesolimab) have shown efficacy in generalized pustular psoriasis, a related condition. This is drug/therapeutic evidence from clinical trials, not from this dataset.
- **Next step**: Validate IL36A/IL36G protein expression by immunohistochemistry in an independent psoriasis cohort; test whether IL-36 pathway blockade reduces keratinocyte-derived AMP and SPRR expression in ex vivo skin models.
- **Conclusion status**: **Supported hypothesis** (not established—the dataset shows association, not causality).

### Priority 2: S100/Defensin Alarmin Module as a Biomarker
- **Classification**: Biomarker
- **Rationale**: S100A7/A7A/A8/A12 and DEFB4A/B are among the most strongly upregulated genes (log2FC 7–11). These secreted proteins could serve as measurable biomarkers of disease activity in blood or skin tape strips.
- **Current evidence**: Direct statistical support; GO annotations (antimicrobial humoral response); STRING network showing S100A7 as a hub.
- **External evidence**: S100A8/A9 (calprotectin) is already used clinically as a fecal biomarker in inflammatory bowel disease and is measurable in serum; S100A7 is detectable in psoriatic scale. Literature support is extensive but overlapping with the direct evidence (many studies have reported S100 upregulation in psoriasis).
- **Next step**: Measure S100A7/A8/A12 and DEFB4 protein levels in serum/plasma from an independent psoriasis cohort and correlate with PASI score; assess whether levels change with treatment.
- **Conclusion status**: **Supported hypothesis** (protein-level validation in independent cohorts is needed).

### Priority 3: Keratinocyte Differentiation Program as a Mechanistic Hypothesis
- **Classification**: Mechanistic hypothesis
- **Rationale**: The coordinated upregulation of SPRR2A–G, SPRR3, LCE3A/LCE3D, and KRT6A defines an aberrant differentiation program. LCE3 deletions are a replicated psoriasis risk locus, suggesting that dysregulation of this genomic region is not merely a consequence but may contribute to pathogenesis.
- **Current evidence**: Direct statistical support; Reactome "Formation of the cornified envelope" annotation; STRING network co-membership.
- **External evidence**: GWAS data (100/100 genes with records) include LCE3B/LCE3C deletion as a psoriasis risk variant; this is genetic evidence independent of the expression data. However, the relationship between germline deletion and the observed LCE3A/LCE3D overexpression requires clarification.
- **Next step**: Test whether IL-17/IL-22/IL-36 stimulation of normal keratinocytes recapitulates the SPRR/LCE/KRT6A induction pattern; examine chromatin accessibility at the LCE locus in psoriatic vs. normal keratinocytes.
- **Conclusion status**: **Supported hypothesis** (the differentiation program is a well-established feature of psoriasis, but the causal relationship between the differentiation defect and inflammation remains to be defined).

### Priority 4: Cell-Composition Confounding Check
- **Classification**: Confounding or composition check
- **Rationale**: Psoriatic lesional skin contains a dense inflammatory infiltrate (T cells, dendritic cells, neutrophils) and altered keratinocyte differentiation. Many of the observed expression changes (e.g., CXCL13, CD274, CXCR2) could reflect differences in cell-type proportions rather than cell-intrinsic transcriptional changes.
- **Current evidence**: The dataset is from bulk tissue; cell-type deconvolution was not performed. The statistical results are valid for the tissue as a whole but do not attribute changes to specific cell types.
- **External evidence**: Single-cell RNA-seq studies of psoriasis have shown that many of these genes (S100A7/A8, SPRRs, IL36) are expressed in specific keratinocyte subpopulations, while CXCL13 and CD274 are expressed in immune cells. This external evidence supports the composition-sensitivity concern.
- **Next step**: Perform single-cell RNA-seq or spatial transcriptomics on matched lesional/non-lesional/control skin; or use computational deconvolution (CIBERSORTx, MuSiC) on the bulk data to estimate cell-type proportions.
- **Conclusion status**: **Exploratory hypothesis** (the confounding effect is plausible but was not directly tested in this dataset).

### Priority 5: Protease-Antiprotease Balance as an Interaction/Network Hypothesis
- **Classification**: Interaction / network hypothesis
- **Rationale**: The co-upregulation of SERPINB3/B4/B11/B13 with KLK13, TMPRSS11D, and PRSS27 suggests a perturbed protease-antiprotease network. SERPINB3/B4 are known to inhibit cysteine proteases and some serine proteases; their induction may protect keratinocytes from immune-cell-derived proteases (e.g., CTSG, neutrophil elastase).
- **Current evidence**: Direct statistical support; STRING network showing CTSG as a connecting node for SERPINB3/B4/B13.
- **External evidence**: SERPINB3/B4 are established markers of psoriatic keratinocyte activation; their induction by IL-17/IL-22 is documented. However, the specific protease targets in the psoriatic lesion are not fully defined.
- **Next step**: Perform protease activity profiling (activity-based protein profiling) on psoriatic vs. normal skin; test whether SERPINB3/B4 knockdown in keratinocyte models increases sensitivity to neutrophil-mediated damage.
- **Conclusion status**: **Exploratory hypothesis** (the network is plausible but the functional consequences are untested).

## 5. Evidence Grounding

### Direct Evidence from Input Dataset
- All 100 genes have FDR ≤ 0.01, with 90 upregulated and 10 downregulated. The most extreme effects are IL36A (log2FC=11.37), DEFB4A (log2FC=11.18), DEFB4B (log2FC=11.03), S100A7A (log2FC=9.83), and PI3 (log2FC=9.24). These are the primary statistical facts.

### Pathway/Ontology Evidence
- Reactome annotations support the IL-36 pathway (IL36RN), IL-20 family signaling (IL19), and cornified envelope formation (12 genes including KLK13, KRT6A, LCE3A, LCE3D, PI3). KEGG annotations support IL-17 signaling and cytokine-cytokine receptor interaction. These are contextual annotations, not statistics computed from this dataset.

### Protein Interaction/Regulatory Evidence
- STRING records show direct physical interactions for the IL-36 module (IL36RN-IL1RL2, confidence=0.999) and potential direct interactions for SERPINB-CTS G. The SPRR/LCE network reflects pathway co-membership rather than physical interaction. These records are from curated databases and may share underlying publications.

### Disease-Association Evidence
- GWAS records are available for 100/100 selected genes, but the specific psoriasis-associated variants were not enumerated in the retrieved context. The LCE3B/LCE3C deletion is a known psoriasis risk variant (genetic evidence), but this is not from the uploaded dataset.

### Expression/Tissue-Specific Evidence
- GTEx records (83/100 genes) and Human Protein Atlas records (76/100 genes) provide tissue-expression context but do not constitute validation of the psoriasis-specific changes.

### Drug/Therapeutic Evidence
- ClinicalTrials.gov records were retrieved for 40/100 genes, and ChEMBL records for 11/100 genes. The presence of a drug targeting a gene does not establish therapeutic efficacy in psoriasis. For example, IL-36 receptor antagonists are in trials for pustular psoriasis, but this is external clinical evidence, not derived from this dataset.

### Literature Evidence
- PubMed (669 articles) and Europe PMC (848 articles) records were retrieved. The most relevant records include a psoriasis biomarker study (PMID 40560938) and a study of KRT6A in alopecia areata (Europe PMC 42216026). Literature support is extensive for S100, defensins, IL-36, and SPRR in psoriasis, but these sources are not independent of the pathway annotations (they may share the same underlying publications).

### Independence Assessment
- The pathway annotations (Reactome, KEGG), interaction records (STRING), and literature records may all derive from overlapping underlying publications. They should not be treated as independent confirmations of each other. The only genuinely independent evidence classes are: (1) the uploaded statistics, (2) germline genetic association data (GWAS), and (3) clinical trial records—and none of these were directly compared to the uploaded statistics in a formal replication analysis.

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue/Cell-Composition Differences
Psoriatic lesional skin contains a dense inflammatory infiltrate and altered keratinocyte differentiation. The bulk-tissue transcriptomic signal conflates cell-intrinsic changes with changes in cell-type proportions. For example, CXCL13 (log2FC=5.89) and CD274 (log2FC=3.44) are likely expressed by infiltrating immune cells rather than keratinocytes. **How to address**: Single-cell RNA-seq or spatial transcriptomics; computational deconvolution of the bulk data; immunohistochemistry to localize protein expression.

### Limitation 2: Disease Severity and Treatment Exposure
The dataset does not specify psoriasis severity (PASI/BSA), disease duration, or prior treatment. Biologic-treated patients may show different transcriptomic profiles than treatment-naive patients. The comparison is lesional vs. normal skin, but non-lesional skin from the same patients was not included—this would help distinguish disease-specific from skin-wide changes. **How to address**: Collect treatment history and severity scores; include non-lesional and resolved-lesion samples.

### Limitation 3: Broad/Nonspecific Pathway Enrichment
Many of the upregulated genes (S100s, defensins, SPRRs, KRT6A) are induced in other inflammatory and hyperproliferative skin conditions (atopic dermatitis, wound healing, squamous cell carcinoma). The specificity of this signature to psoriasis is not established by this dataset alone. **How to address**: Compare with transcriptomic data from other inflammatory skin diseases; identify psoriasis-specific gene combinations or regulatory networks.

### Limitation 4: Association-versus-Causation Ambiguity
The direction of causality cannot be determined from a cross-sectional comparison. The IL-36/IL-20 upregulation could drive the keratinocyte differentiation changes, or the keratinocyte defect could trigger the inflammatory response, or both could be downstream of a shared trigger. **How to address**: Time-course experiments in ex vivo skin models; genetic perturbation (e.g., IL36RN knockout) in organotypic cultures; Mendelian randomization using psoriasis GWAS variants.

### Limitation 5: Batch/Platform Effects and Technical Artifacts
The dataset does not specify the sequencing platform, batch structure, or normalization method. The extreme log2FC values (e.g., IL36A at 11.37, DEFB4A at 11.18) are unusually large and could reflect low baseline expression in normal skin (making fold-change estimates unstable) or technical issues. **How to address**: Verify with qPCR or NanoString on independent samples; examine raw counts and normalization diagnostics; check for platform-specific biases.

---

**In summary, this dataset provides strong statistical evidence for a coordinated IL-36/IL-20-driven inflammatory program with antimicrobial peptide induction, aberrant keratinocyte differentiation, and protease-antiprotease imbalance in psoriatic lesional skin, but the causal relationships, cell-type specificity, and disease specificity require independent validation through single-cell studies, protein-level confirmation, and comparison with other inflammatory skin conditions.**

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=60, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
